The incidence of metabolic syndrome (MetS) worldwide has markedly surged with industrialized development and improved food distribution.1 It is marked by the presence of obesity by waist circumference and two or more of the following characteristics1:
- Hypertriglyceridemia: ≥ 150 mg/dL, or under treatment for this lipid abnormality.
- HDL-cholesterolemia below recommendations:
- Hypertension: systolic ≥ 130 mmHg and/or diastolic ≥ 85 mmHg over 24 h.
- Fasting Hyperglycemia: ≥100 mg/dL, hyperinsulinemia, or type 2 diabetes.
With this increased rate, the need for an array of resources will be needed to mitigate its effects. Currently there is a shortage of insulin available, and it is especially acute among developing countries. The purchase of insulins can consume as much as 10% of government expenditure on drugs.2
Research that may provide alternative solutions would be beneficial to countless people worldwide. To that end, Peptides International has a diverse and broad portfolio of feeding-regulatory products, with many applications for research of MetS, along with numerous other endocrine-associated diseases.
The most recent to be added are four offerings representing both peptides and proteins.
We featured Relaxin-3 (PRO-2176) just last fall and now we are adding another pair, Relaxin-2 Human Recombinant (PRO-1327)and Relaxin-2 (Human) (REX-4509-v).They may have other roles in boosting sperm motility, regulating blood pressure, controlling heart rate and releasing vasopressin. RLN2 is a peptide hormone linked to several therapeutically relevant physiological effects, including regulation of collagen metabolism and multiple vascular control pathways.
Our third product has recently released corresponding items too. Those were featured in a PepTalk from late February: Neuromedin U Precursor-Related Peptide 36 (Rat, Mouse) (PMN-4506-s), Neuromedin S Precursor-Related Peptide 37 (Rat) (PNM-4507-s), and Neuromedin S Precursor-Related Peptide 37 (Mouse) (PMN-4508-s). Now we also have Neuromedin S (Mouse) (PNM-4496-s).
The fourth member of this quartet is Pentosidine (SAE-3242-v) which is an Advanced Glycation End Product (AGE) and a biomarker for glycation-oxidative stress (e.g. in type 2 diabetes and aging).
M. Etchegoyen, M.H. Nobile, F. Baez, B. Posesorski, J. González, N. Lago, J. Milei and M. Otero-Losada, Front. Neurosci., 12, 196 (2018). doi: 10.3389/fnins.2018.00196
G.V. Gill, J.S. Yudkin, H. Keen, D. Beran, Diabetologia, 54, 1 (2011).